M-VAC and MAC Combination Chemotherapy in Advanced Bladder Cancer.
- Author:
Hun Goo KANG
1
;
Jun Ho CHANG
Author Information
1. Department of Urology, Dong- Bu Seoul City Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Advanced bladder tumor;
M-VAC and MAC combination chemotherapy
- MeSH:
Doxorubicin;
Drug Therapy, Combination*;
Humans;
Liver;
Lung;
Urinary Bladder Neoplasms*;
Urinary Bladder*;
Vinblastine
- From:Korean Journal of Urology
1990;31(6):814-819
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Of the 11 advanced bladder cancer patients who received M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) combination chemotherapy, complete and partial remission were observed in 63.6%. Of the 17 advanced bladder cancer patients who received MAC (Methotrexate, Doxorubicin and Cisplatin) combination chemotherapy, complete and partial remissions were observed in 17%. Complete remission was achieved in 18.2% of the patients clinically, pathologically in M-VAC group and 5.9% in MAC group. Partial remission was occurred in 46.5% of the patients in M-VAC group and 41.2% in MAC group. All metastatic sites including the bone and liver, lung were well responded in M-VAC group, but poorly responded in MAC group. Toxicity was significant but tolerable.
